Merck Outlines Its Criteria For Biotech Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO describes the criteria Merck is using to evaluate a potential biotech acquisition at JP Morgan Healthcare Conference.
You may also be interested in...
Big Pharma Is Paying More, Earlier For Biotechs
Acquisition deals become more expensive as pharmas compete to fill pipelines, execs say at BIO meeting in Boston.
Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
King's CorVu Gets Reluctant "No" From Advisory Committee
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.